Does Network Health Cover Eliquis? A Woman's Complete Guide to Coverage, Cost, and Safety

Does Network Health Actually Cover Eliquis?

Network Health, a regional health plan operating primarily in Wisconsin, covers Eliquis (apixaban) on most of its commercial and Medicare plans, but placement on the formulary varies by plan year and product line. For the majority of commercially insured members, Eliquis lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which carries a higher cost-share than generic medications. Medicare Advantage and Part D plans from Network Health follow CMS formulary rules, and CMS data confirm apixaban appears on most Part D formularies at varying tiers with coverage gap implications.

The only definitive way to verify your current-year coverage is to:

1. Log into your Network Health member portal and run a drug search under "Formulary."
2. Call the member services number printed on your insurance card and ask for the formulary tier, copay, and whether prior authorization (PA) applies to your diagnosis code.
3. Ask your prescribing clinician's office to submit a PA request proactively if your plan requires one.

Prior authorization is the most common barrier. Plans typically require documented evidence of the approved indication, such as nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), or surgical VTE prophylaxis after hip or knee replacement.

What Prior Authorization Typically Requires

For most commercial plans similar to Network Health, a PA for Eliquis generally requires your clinician to document:

• Confirmed diagnosis (ICD-10 code) matching an FDA-approved indication
• Reason a lower-cost anticoagulant (such as warfarin or a different DOAC like rivaroxaban) is not appropriate, or that it was tried and failed
• Current renal function (creatinine clearance), because dose selection depends on kidney function
• Body weight and age for dose-reduction criteria

PA approval usually covers a 12-month period and must be renewed annually. Women who are started on Eliquis during a hospitalization for DVT or PE sometimes find their outpatient plan requires a separate PA even when the hospital approved it.

Why Women's Eliquis Coverage Questions Are Clinically Different

Women face a distinct set of conditions that both increase VTE risk and complicate insurance coverage conversations. The following conditions are common in female patients and directly affect whether Eliquis is medically necessary and therefore coverable.

PCOS and Elevated Clot Risk

Polycystic ovary syndrome (PCOS) affects an estimated 8 to 13 percent of reproductive-age women worldwide. Beyond its metabolic and hormonal effects, PCOS is associated with a prothrombotic state: elevated plasminogen activator inhibitor-1 (PAI-1), higher fibrinogen, and in women who also use combined oral contraceptives (COCs) as part of their PCOS management, a compounded VTE risk. If you have PCOS and develop a DVT or PE, Eliquis is one of the preferred anticoagulants, and documenting PCOS plus your specific clot event strengthens a prior-authorization submission.

Hormonal Contraception and VTE

Combined hormonal contraceptives raise VTE risk approximately 3-fold compared to non-users, and that risk increases further with factor V Leiden or other thrombophilias. Women who develop a clot on COCs are often switched to a progestin-only method while receiving anticoagulation. Your plan's PA request should explicitly note the contribution of hormonal contraception to your clot event.

Perimenopause and Atrial Fibrillation

Atrial fibrillation (AF) incidence rises with age, and women develop AF about a decade later than men on average but carry a higher absolute stroke risk once diagnosed. Perimenopausal women aged 45 to 55 with new-onset AF are increasingly candidates for Eliquis. The ARISTOTLE trial, which enrolled 18,201 patients with nonvalvular AF, showed apixaban reduced stroke or systemic embolism by 21% compared to warfarin (HR 0.79, 95% CI 0.66-0.95) and caused significantly less major bleeding. Women comprised about 35% of that trial population, a proportion that reflects the historical under-enrollment of women in cardiovascular trials. Subgroup analyses did not show a statistically significant sex-based difference in efficacy, but women in ARISTOTLE had higher rates of major bleeding on warfarin than men, making the switch to apixaban potentially more beneficial for women.

Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) is far more common in women and is a specific situation where Eliquis use requires caution. The TRAPS trial (NCT02157272) found rivaroxaban inferior to warfarin in high-risk triple-positive APS patients. ACOG and the American College of Rheumatology currently recommend warfarin over DOACs (including apixaban) for thrombotic APS with triple positivity. If you have APS, confirm with your hematologist or rheumatologist whether Eliquis is the right anticoagulant before pursuing coverage.

Sex-Specific Pharmacokinetics: How Eliquis Works Differently in Women

Apixaban is a direct Factor Xa inhibitor. Its pharmacokinetics (PK) are not dramatically sex-stratified in FDA labeling, but real-world and sub-study data reveal meaningful differences worth knowing.

Body weight affects drug exposure. Women have lower average body weight than men, and very low body weight (under 50 kg) increases apixaban peak plasma concentration by approximately 27%, according to population PK modeling. This means low-weight women may reach higher drug levels at standard doses, slightly increasing bleeding risk.

The dose-reduction criteria in the FDA label are: age 80 years or older, body weight 60 kg or less, and serum creatinine 1.5 mg/dL or higher. Patients meeting at least 2 of these 3 criteria receive 2.5 mg twice daily instead of 5 mg twice daily. Women, who on average live longer and weigh less than men, are more likely to meet these dose-reduction criteria.

Renal function matters here too. Creatinine-based estimates of kidney function (like CrCl via Cockcroft-Gault) can overestimate kidney function in older, low-muscle-mass women. Using actual body weight rather than ideal body weight in the Cockcroft-Gault equation is generally recommended for women at the lower end of the weight spectrum, and your prescribing clinician should document the specific equation and inputs used when justifying a dose for a PA submission.

The WomanRx Three-Step Coverage-to-Dose Framework for Women Starting Eliquis:

1. Confirm indication-specific PA requirements with your plan before the first fill.
2. Ask your clinician to document your actual body weight, age, and creatinine explicitly in the PA request, because dose reduction criteria affect both safety and coverage logic.
3. If you are perimenopausal or postmenopausal and on systemic hormone therapy (HT), discuss whether your HT route (transdermal vs. Oral) affects your clot risk, because transdermal estradiol carries lower VTE risk than oral estrogen and your clinician may want to adjust your HT rather than assume anticoagulation alone is sufficient.

Pregnancy, Lactation, and Contraception: What Every Woman on Eliquis Must Know

Eliquis is contraindicated in pregnancy. This is not a precautionary soft warning. Apixaban crosses the placenta in animal studies, and no adequate human data exist to establish safety. The FDA prescribing information for apixaban classifies it as a drug with potential fetal harm based on the mechanism of action (anticoagulation of a developing fetus carries hemorrhagic risk) and animal reproduction studies showing increased fetal resorptions and reduced fetal weight.

If You Are Pregnant and Need Anticoagulation

Pregnant women who require anticoagulation (for DVT, PE, mechanical heart valves, or APS) should use low-molecular-weight heparin (LMWH), specifically enoxaparin, which does not cross the placenta in clinically significant amounts. ACOG Practice Bulletin No. 196 covers VTE management in pregnancy and clearly recommends LMWH over all oral anticoagulants throughout pregnancy and the postpartum period until bleeding risk decreases. Warfarin is sometimes used after the first trimester for specific indications like mechanical valves, but Eliquis is not an accepted substitute in any trimester.

Postpartum and Breastfeeding

Apixaban transfer into human breast milk has not been adequately studied. The FDA label states that breastfeeding is not recommended during apixaban treatment because of potential serious adverse reactions in the nursing infant. Postpartum VTE risk peaks in the first 6 weeks after delivery. If you develop a clot in this window and are breastfeeding, discuss with your hematologist or OB whether temporarily pumping and discarding, or transitioning to LMWH, is appropriate for your situation.

Contraception Requirement

Eliquis itself does not require contraception in the way teratogenic drugs like isotretinoin or valproate do. There is no mandated pregnancy prevention program (like iPLEDGE). However, because fetal exposure carries meaningful bleeding risk and there is no safe dose in pregnancy, any woman of reproductive age starting Eliquis should:

• Discuss a reliable contraception plan with her clinician
• Avoid combined hormonal contraceptives if her clot risk is already elevated (pill-related VTE risk compounds the underlying condition)
• Consider a levonorgestrel IUD or progestin-only pill, both of which carry lower VTE risk than COCs
• Use a home pregnancy test promptly if a period is missed, because dose switching to LMWH early in pregnancy is far safer than delayed transition

How Much Does Eliquis Cost Out of Pocket, and How Can Women Reduce It?

Without insurance, a 30-day supply of Eliquis 5 mg twice daily (60 tablets) retails at approximately $550 to $620 at major U.S. Pharmacies. With a Tier 3 or Tier 4 commercial copay, cost-share typically runs $50 to $150 per 30-day supply depending on your deductible status.

Manufacturer Savings Card

Bristol-Myers Squibb and Pfizer offer the Eliquis 360 Support savings program for commercially insured patients. Eligible patients may pay as little as $10 per month. This card cannot be used with Medicare, Medicaid, or any federal health insurance program. To apply, your clinician's office can enroll you, or you can register directly on the manufacturer site.

Generic Apixaban

The FDA approved generic apixaban in May 2024 after the primary patent expiration. Generic versions from multiple manufacturers are now entering the market, which should reduce both list prices and formulary tier placement on many plans over the next 12 to 18 months. Ask your pharmacy specifically whether a generic apixaban is in stock and whether your plan covers it at a lower tier than branded Eliquis.

Prior Authorization Denial and Appeals

If your Network Health plan denies coverage:

1. Request the denial in writing with the specific reason code.
2. Ask your clinician to submit a peer-to-peer review call with the plan's medical director, citing the ARISTOTLE or AMPLIFY trial data supporting apixaban's efficacy and safety.
3. File a formal appeal. CMS guidelines require Medicare plans to resolve expedited appeals within 72 hours for urgent medical situations.
4. If appeals fail, ask about step therapy exceptions if your clinician believes warfarin or another DOAC is clinically inferior for your specific case (relevant for women with renal impairment, certain drug interactions, or history of poor INR control on warfarin).

Who This Is Right For, and Who Should Pause

Women Who Are Likely Good Candidates for Eliquis

• Women with nonvalvular AF, especially perimenopausal and postmenopausal women who want to avoid monthly INR monitoring required with warfarin
• Women with a first unprovoked DVT or PE and adequate renal function (CrCl above 25 mL/min per the FDA label)
• Women with provoked VTE related to surgery, prolonged immobility, or hormonal contraception
• Women with a history of poor warfarin control (time in therapeutic range below 65%) or who have occupations or lifestyles incompatible with frequent blood draws
• Low-weight or older women who meet dose-reduction criteria and need a predictable drug level without routine monitoring

Women Who Should Reconsider or Use a Different Agent

• Pregnant women at any stage (use LMWH instead)
• Women with high-risk triple-positive antiphospholipid syndrome (warfarin is preferred per current evidence)
• Women with severe renal impairment (CrCl below 15 mL/min), where data are insufficient
• Women with active pathological bleeding
• Women on strong dual inhibitors of CYP3A4 and P-gp (such as certain antifungals like ketoconazole), which can increase apixaban exposure by approximately 2-fold

Eliquis Across the Female Life Span

Reproductive Years (Ages 18 to 40)

Young women on combined hormonal contraceptives who develop DVT need anticoagulation promptly and a contraceptive switch. Eliquis is appropriate for treatment, but the combined estrogen-containing pill must be stopped. A copper IUD, progestin-only pill, or levonorgestrel IUD becomes the preferred contraceptive during and sometimes after anticoagulation.

Women with inherited thrombophilias (factor V Leiden, prothrombin gene mutation) who are planning pregnancy need a comprehensive plan from a maternal-fetal medicine specialist because LMWH, not Eliquis, is the anticoagulant of choice throughout pregnancy and the postpartum period.

Perimenopause (Ages 45 to 55)

This is the window where AF incidence begins to rise. The Framingham Heart Study found that lifetime AF risk at age 55 was approximately 37% for women. New-onset AF in the perimenopausal decade often prompts the first anticoagulation conversation. Women on systemic hormone therapy who develop AF should discuss route of estrogen delivery with their clinician; transdermal estradiol carries a lower VTE risk than oral estradiol and may be continued alongside anticoagulation in most cases.

Postmenopause (Ages 55 and Above)

Postmenopausal women are more likely to meet the Eliquis dose-reduction criteria (age 80+, weight below 60 kg, elevated creatinine). Bone health is a secondary consideration: some evidence suggests vitamin K antagonists like warfarin reduce bone mineral density more than DOACs, giving apixaban a potential advantage in osteoporosis-prone postmenopausal women, though this is not yet a primary indication consideration and should not drive anticoagulant selection alone.

Evidence Gaps: What We Do Not Yet Know About Eliquis in Women

Women were substantially under-enrolled in the key DOAC trials. In ARISTOTLE, women were approximately 35% of the trial population. In the AMPLIFY trial evaluating apixaban for VTE treatment, women represented about 42% of participants. Sex-stratified analyses have generally shown consistent efficacy, but the confidence intervals in female subgroups are wider, meaning we have less precision about the true effect size in women.

Specifically, the following questions remain inadequately answered in women:

• Optimal dosing in very low body weight women (below 45 kg)
• Apixaban PK across the menstrual cycle (estrogen and progesterone fluctuations may affect drug metabolism through CYP3A4 activity changes, but no dedicated studies have been published)
• Long-term safety data in women with PCOS receiving anticoagulation alongside metformin or combined hormonal contraceptives
• Comparative effectiveness versus warfarin specifically in women with lupus-associated thrombosis not meeting full APS criteria

These are areas where WomanRx recommends asking your clinician directly: "Is the dose you are prescribing based on data from women who look like me, or is it extrapolated from a predominantly male trial?"

Talking to Your Network Health Plan: A Script

When you call member services, ask these specific questions and write down the representative's name and the date:

1. "Is apixaban (Eliquis) on my formulary for plan year 2025?"
2. "What tier is it on, and what is my copay for a 30-day and 90-day supply?"
3. "Does my plan require prior authorization for apixaban for [your diagnosis]?"
4. "Is there a preferred alternative DOAC on a lower tier?"
5. "If I am denied, what is the appeal process and how long does it take?"

Document everything. A PA denial is not the end of the process. Peer-to-peer reviews succeed in roughly 50% of cases when the prescribing clinician can speak directly with the plan's medical director with trial-level data in hand.